Myriad Genetics is expected to report Q3 2026 revenue of $215.4 million and an adjusted EPS of $0.05, with the current stock price of $28.45 trading below the average analyst price target of $33.50.
Investors are primarily focused on the volume growth of the GeneSight pharmacogenomics test, which remains the company's most significant growth driver. Recent performance has been bolstered by double-digit growth in hereditary cancer testing and prenatal volumes. Market participants are also looking for updates on the company's 2026 long-term profitability targets and laboratory efficiency improvements.